HRP20211527T1 - Il-8 inhibitori za primjenu u liječenju periferne neuropatije izazvane kemoterapijom - Google Patents
Il-8 inhibitori za primjenu u liječenju periferne neuropatije izazvane kemoterapijom Download PDFInfo
- Publication number
- HRP20211527T1 HRP20211527T1 HRP20211527TT HRP20211527T HRP20211527T1 HR P20211527 T1 HRP20211527 T1 HR P20211527T1 HR P20211527T T HRP20211527T T HR P20211527TT HR P20211527 T HRP20211527 T HR P20211527T HR P20211527 T1 HRP20211527 T1 HR P20211527T1
- Authority
- HR
- Croatia
- Prior art keywords
- inhibitor
- alkyl
- linear
- use according
- branched
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title claims 22
- 238000002512 chemotherapy Methods 0.000 title claims 6
- 208000033808 peripheral neuropathy Diseases 0.000 title claims 5
- 102000004890 Interleukin-8 Human genes 0.000 claims 21
- 108090001007 Interleukin-8 Proteins 0.000 claims 21
- 150000001875 compounds Chemical class 0.000 claims 9
- 229910052739 hydrogen Inorganic materials 0.000 claims 7
- 239000001257 hydrogen Substances 0.000 claims 7
- BASFCYQUMIYNBI-UHFFFAOYSA-N platinum Chemical compound [Pt] BASFCYQUMIYNBI-UHFFFAOYSA-N 0.000 claims 6
- 150000003839 salts Chemical class 0.000 claims 6
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 4
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 claims 4
- 229940123237 Taxane Drugs 0.000 claims 3
- 125000003236 benzoyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C(*)=O 0.000 claims 3
- 229940079593 drug Drugs 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 3
- 229910052697 platinum Inorganic materials 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 159000000000 sodium salts Chemical class 0.000 claims 3
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- UEJJHQNACJXSKW-UHFFFAOYSA-N 2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione Chemical compound O=C1C2=CC=CC=C2C(=O)N1C1CCC(=O)NC1=O UEJJHQNACJXSKW-UHFFFAOYSA-N 0.000 claims 2
- 108010018976 Interleukin-8A Receptors Proteins 0.000 claims 2
- 229930012538 Paclitaxel Natural products 0.000 claims 2
- 125000000217 alkyl group Chemical group 0.000 claims 2
- GXJABQQUPOEUTA-RDJZCZTQSA-N bortezomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)B(O)O)NC(=O)C=1N=CC=NC=1)C1=CC=CC=C1 GXJABQQUPOEUTA-RDJZCZTQSA-N 0.000 claims 2
- 229960001467 bortezomib Drugs 0.000 claims 2
- 229910052799 carbon Inorganic materials 0.000 claims 2
- 125000004432 carbon atom Chemical group C* 0.000 claims 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims 2
- BLMPQMFVWMYDKT-NZTKNTHTSA-N carfilzomib Chemical compound C([C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CC(C)C)C(=O)[C@]1(C)OC1)NC(=O)CN1CCOCC1)CC1=CC=CC=C1 BLMPQMFVWMYDKT-NZTKNTHTSA-N 0.000 claims 2
- 229960002438 carfilzomib Drugs 0.000 claims 2
- 108010021331 carfilzomib Proteins 0.000 claims 2
- 239000012829 chemotherapy agent Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 229960003649 eribulin Drugs 0.000 claims 2
- UFNVPOGXISZXJD-XJPMSQCNSA-N eribulin Chemical compound C([C@H]1CC[C@@H]2O[C@@H]3[C@H]4O[C@H]5C[C@](O[C@H]4[C@H]2O1)(O[C@@H]53)CC[C@@H]1O[C@H](C(C1)=C)CC1)C(=O)C[C@@H]2[C@@H](OC)[C@@H](C[C@H](O)CN)O[C@H]2C[C@@H]2C(=C)[C@H](C)C[C@H]1O2 UFNVPOGXISZXJD-XJPMSQCNSA-N 0.000 claims 2
- 125000005842 heteroatom Chemical group 0.000 claims 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 2
- GOTYRUGSSMKFNF-UHFFFAOYSA-N lenalidomide Chemical compound C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O GOTYRUGSSMKFNF-UHFFFAOYSA-N 0.000 claims 2
- 229960004942 lenalidomide Drugs 0.000 claims 2
- 230000001404 mediated effect Effects 0.000 claims 2
- 201000001119 neuropathy Diseases 0.000 claims 2
- 230000007823 neuropathy Effects 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 claims 2
- 229960001756 oxaliplatin Drugs 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 229960001592 paclitaxel Drugs 0.000 claims 2
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims 2
- UVSMNLNDYGZFPF-UHFFFAOYSA-N pomalidomide Chemical compound O=C1C=2C(N)=CC=CC=2C(=O)N1C1CCC(=O)NC1=O UVSMNLNDYGZFPF-UHFFFAOYSA-N 0.000 claims 2
- 229960000688 pomalidomide Drugs 0.000 claims 2
- 229910052717 sulfur Inorganic materials 0.000 claims 2
- RCINICONZNJXQF-MZXODVADSA-N taxol Chemical compound O([C@@H]1[C@@]2(C[C@@H](C(C)=C(C2(C)C)[C@H](C([C@]2(C)[C@@H](O)C[C@H]3OC[C@]3([C@H]21)OC(C)=O)=O)OC(=O)C)OC(=O)[C@H](O)[C@@H](NC(=O)C=1C=CC=CC=1)C=1C=CC=CC=1)O)C(=O)C1=CC=CC=C1 RCINICONZNJXQF-MZXODVADSA-N 0.000 claims 2
- 229960003433 thalidomide Drugs 0.000 claims 2
- 125000005951 trifluoromethanesulfonyloxy group Chemical group 0.000 claims 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims 2
- OUGCUPYREMACGK-ZETCQYMHSA-N (2s)-2-[4-[[4-(trifluoromethyl)-1,3-thiazol-2-yl]amino]phenyl]propanoic acid Chemical compound C1=CC([C@@H](C(O)=O)C)=CC=C1NC1=NC(C(F)(F)F)=CS1 OUGCUPYREMACGK-ZETCQYMHSA-N 0.000 claims 1
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 1
- 125000006656 (C2-C4) alkenyl group Chemical group 0.000 claims 1
- 125000006650 (C2-C4) alkynyl group Chemical group 0.000 claims 1
- TVKXUJXIOMUVFS-UHFFFAOYSA-N 2-methyl-2-[4-[[4-(trifluoromethyl)-1,3-thiazol-2-yl]amino]phenyl]propanoic acid Chemical compound C1=CC(C(C)(C(O)=O)C)=CC=C1NC1=NC(C(F)(F)F)=CS1 TVKXUJXIOMUVFS-UHFFFAOYSA-N 0.000 claims 1
- 102100036166 C-X-C chemokine receptor type 1 Human genes 0.000 claims 1
- 125000000882 C2-C6 alkenyl group Chemical group 0.000 claims 1
- 101100294106 Caenorhabditis elegans nhr-3 gene Proteins 0.000 claims 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 1
- 208000004454 Hyperalgesia Diseases 0.000 claims 1
- 108010018951 Interleukin-8B Receptors Proteins 0.000 claims 1
- 102000002791 Interleukin-8B Receptors Human genes 0.000 claims 1
- KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 claims 1
- 239000004472 Lysine Substances 0.000 claims 1
- ZDZOTLJHXYCWBA-VCVYQWHSSA-N N-debenzoyl-N-(tert-butoxycarbonyl)-10-deacetyltaxol Chemical compound O([C@H]1[C@H]2[C@@](C([C@H](O)C3=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=4C=CC=CC=4)C[C@]1(O)C3(C)C)=O)(C)[C@@H](O)C[C@H]1OC[C@]12OC(=O)C)C(=O)C1=CC=CC=C1 ZDZOTLJHXYCWBA-VCVYQWHSSA-N 0.000 claims 1
- 206010061323 Optic neuropathy Diseases 0.000 claims 1
- JXLYSJRDGCGARV-WWYNWVTFSA-N Vinblastine Natural products O=C(O[C@H]1[C@](O)(C(=O)OC)[C@@H]2N(C)c3c(cc(c(OC)c3)[C@]3(C(=O)OC)c4[nH]c5c(c4CCN4C[C@](O)(CC)C[C@H](C3)C4)cccc5)[C@@]32[C@H]2[C@@]1(CC)C=CCN2CC3)C JXLYSJRDGCGARV-WWYNWVTFSA-N 0.000 claims 1
- 125000004442 acylamino group Chemical group 0.000 claims 1
- 125000004423 acyloxy group Chemical group 0.000 claims 1
- 229930013930 alkaloid Natural products 0.000 claims 1
- 125000003342 alkenyl group Chemical group 0.000 claims 1
- 125000003545 alkoxy group Chemical group 0.000 claims 1
- 206010053552 allodynia Diseases 0.000 claims 1
- 239000002246 antineoplastic agent Substances 0.000 claims 1
- VSRXQHXAPYXROS-UHFFFAOYSA-N azanide;cyclobutane-1,1-dicarboxylic acid;platinum(2+) Chemical compound [NH2-].[NH2-].[Pt+2].OC(=O)C1(C(O)=O)CCC1 VSRXQHXAPYXROS-UHFFFAOYSA-N 0.000 claims 1
- 229960001573 cabazitaxel Drugs 0.000 claims 1
- BMQGVNUXMIRLCK-OAGWZNDDSA-N cabazitaxel Chemical compound O([C@H]1[C@@H]2[C@]3(OC(C)=O)CO[C@@H]3C[C@@H]([C@]2(C(=O)[C@H](OC)C2=C(C)[C@@H](OC(=O)[C@H](O)[C@@H](NC(=O)OC(C)(C)C)C=3C=CC=CC=3)C[C@]1(O)C2(C)C)C)OC)C(=O)C1=CC=CC=C1 BMQGVNUXMIRLCK-OAGWZNDDSA-N 0.000 claims 1
- 229960004562 carboplatin Drugs 0.000 claims 1
- 229960004316 cisplatin Drugs 0.000 claims 1
- DQLATGHUWYMOKM-UHFFFAOYSA-L cisplatin Chemical compound N[Pt](N)(Cl)Cl DQLATGHUWYMOKM-UHFFFAOYSA-L 0.000 claims 1
- -1 cyano, nitro, amino Chemical group 0.000 claims 1
- 125000000753 cycloalkyl group Chemical group 0.000 claims 1
- 229940127089 cytotoxic agent Drugs 0.000 claims 1
- 229960003668 docetaxel Drugs 0.000 claims 1
- 229930013356 epothilone Natural products 0.000 claims 1
- 150000003883 epothilone derivatives Chemical class 0.000 claims 1
- 229960005420 etoposide Drugs 0.000 claims 1
- VJJPUSNTGOMMGY-MRVIYFEKSA-N etoposide Chemical compound COC1=C(O)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O[C@H]3[C@@H]([C@@H](O)[C@@H]4O[C@H](C)OC[C@H]4O3)O)[C@@H]3[C@@H]2C(OC3)=O)=C1 VJJPUSNTGOMMGY-MRVIYFEKSA-N 0.000 claims 1
- 125000001188 haloalkyl group Chemical group 0.000 claims 1
- 229910052736 halogen Inorganic materials 0.000 claims 1
- 150000002367 halogens Chemical class 0.000 claims 1
- 150000002431 hydrogen Chemical group 0.000 claims 1
- 238000011065 in-situ storage Methods 0.000 claims 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims 1
- 229960002014 ixabepilone Drugs 0.000 claims 1
- FABUFPQFXZVHFB-CFWQTKTJSA-N ixabepilone Chemical compound C/C([C@@H]1C[C@@H]2O[C@]2(C)CCC[C@@H]([C@@H]([C@H](C)C(=O)C(C)(C)[C@H](O)CC(=O)N1)O)C)=C\C1=CSC(C)=N1 FABUFPQFXZVHFB-CFWQTKTJSA-N 0.000 claims 1
- 208000020911 optic nerve disease Diseases 0.000 claims 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 1
- 125000003884 phenylalkyl group Chemical group 0.000 claims 1
- 229940080818 propionamide Drugs 0.000 claims 1
- KQDRVXQXKZXMHP-LLVKDONJSA-N reparixin Chemical compound CC(C)CC1=CC=C([C@@H](C)C(=O)NS(C)(=O)=O)C=C1 KQDRVXQXKZXMHP-LLVKDONJSA-N 0.000 claims 1
- DKPFODGZWDEEBT-QFIAKTPHSA-N taxane Chemical class C([C@]1(C)CCC[C@@H](C)[C@H]1C1)C[C@H]2[C@H](C)CC[C@@H]1C2(C)C DKPFODGZWDEEBT-QFIAKTPHSA-N 0.000 claims 1
- 229960003048 vinblastine Drugs 0.000 claims 1
- JXLYSJRDGCGARV-XQKSVPLYSA-N vincaleukoblastine Chemical compound C([C@@H](C[C@]1(C(=O)OC)C=2C(=CC3=C([C@]45[C@H]([C@@]([C@H](OC(C)=O)[C@]6(CC)C=CCN([C@H]56)CC4)(O)C(=O)OC)N3C)C=2)OC)C[C@@](C2)(O)CC)N2CCC2=C1NC1=CC=CC=C21 JXLYSJRDGCGARV-XQKSVPLYSA-N 0.000 claims 1
- 229960004528 vincristine Drugs 0.000 claims 1
- OGWKCGZFUXNPDA-XQKSVPLYSA-N vincristine Chemical compound C([N@]1C[C@@H](C[C@]2(C(=O)OC)C=3C(=CC4=C([C@]56[C@H]([C@@]([C@H](OC(C)=O)[C@]7(CC)C=CCN([C@H]67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)C[C@@](C1)(O)CC)CC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-XQKSVPLYSA-N 0.000 claims 1
- OGWKCGZFUXNPDA-UHFFFAOYSA-N vincristine Natural products C1C(CC)(O)CC(CC2(C(=O)OC)C=3C(=CC4=C(C56C(C(C(OC(C)=O)C7(CC)C=CCN(C67)CC5)(O)C(=O)OC)N4C=O)C=3)OC)CN1CCC1=C2NC2=CC=CC=C12 OGWKCGZFUXNPDA-UHFFFAOYSA-N 0.000 claims 1
- GBABOYUKABKIAF-GHYRFKGUSA-N vinorelbine Chemical compound C1N(CC=2C3=CC=CC=C3NC=22)CC(CC)=C[C@H]1C[C@]2(C(=O)OC)C1=CC([C@]23[C@H]([C@]([C@H](OC(C)=O)[C@]4(CC)C=CCN([C@H]34)CC2)(O)C(=O)OC)N2C)=C2C=C1OC GBABOYUKABKIAF-GHYRFKGUSA-N 0.000 claims 1
- 229960002066 vinorelbine Drugs 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Claims (14)
1. IL-8 inhibitor za primjenu u prevenciji i/ili liječenju neuropatije izazvane kemoterapijom, pri čemu je navedeni IL-8 inhibitor:
spoj formule (I)
[image]
pri čemu
- R1 je vodik ili CH3;
- R2 je vodik ili linearni C1-C4 alkil, poželjno je vodik;
- Y je heteroatom izabran od S, O i N; poželjno je S;
- Z je izabran od halogena, linearnog ili razgranatog C1-C4 alkila, C2-C4 alkenila, C2-C4 alkinila, C1-C4 alkoksi, hidroksila, karboksila, C1-C4 aciloksi, fenoksi, cijano, nitro, amino, C1-C4 acilamino , halo C1-C3 alkila, halo C1-C3 alkoksi, benzoila, linearnog ili razgranatog C1-C8 alkansulfonata, linearnog ili razgranatog C1-C8 alkansulfonamida, linearnog ili razgranatog C1-C8 alkilsulfonilmetila; poželjno je to trifluorometil;
- X je OH ili ostatak formule NHR3; pri čemu se R3 bira između:
- vodika, hidroksila, linearnog ili razgranatog C1-C6 alkila, C3-C6 cikloalkila, C2-C6 alkenila, C1-C5 alkoksi, ili
- C1-C6 fenilalkila, pri čemu alkil, cikloalkil ili alkenil grupa može biti supstituirana sa COOH ostatkom, ili
- ostatak formule SO2R4 gdje je R4 C1-C2 alkil, C3-C6 cikloalkil, C1-C3 haloalkil;
ili
spoj formule (II)
[image]
ili farmaceutski prihvatljive soli istog,
pri čemu:
- R4 je linearni ili razgranati C1-C6 alkil, benzoil, fenoksi, trifluorometansulfoniloksi; poželjno se bira između benzoila, izobutila i trifluorometansulfoniloksi.
- R5 je H ili linearni ili razgranati C1-C3 alkil, poželjno je H;
- R6 je linearni ili razgranati C1-C6 alkil ili trifluorometil; poželjno, to je linearni ili razgranati C1-C6 alkil, poželjnije CH3.
2. IL-8 inhibitor za primjenu prema patentnom zahtjevu 1 u prevenciji i/ili liječenju periferne neuropatije izazvane kemoterapijom ili optičke neuropatije izazvane kemoterapijom.
3. IL-8 inhibitor za primjenu prema patentnom zahtjevu 2 u prevenciji i/ili liječenju alodinije koja je u vezi sa perifernom neuropatijom izazvanom kemoterapijom.
4. IL-8 inhibitor za primjenu prema patentnim zahtjevima 1 do 3, gdje navedeni IL-8 inhibitor je inhibitor aktivnosti IL-8 posredovane receptorom CXCR1.
5. IL-8 inhibitor za primjenu prema patentnim zahtjevima 1 do 4, gdje navedeni IL-8 inhibitor je inhibitor aktivnosti IL-8 posredovane i CXCR1 i CXCR2 receptorom
6. IL-8 inhibitor za primjenu prema patentnom zahtjevu 1 do 5, gdje je navedeni IL-8 inhibitor spoj formule (I), pri čemu:
- R1 je vodik ili CH3;
- X je OH;
- R2 je vodik ili linearni C1-C4 alkil,
- Y je heteroatom izabran od S, O i N;
- Z je izabran od linearnog ili razgranatog C1-C4 alkila, linearnog ili razgranatog C1-C4 alkoksi, halo C1-C3 alkila i halo C1-C3 alkoksi.
7. IL-8 inhibitor za primjenu prema patentnom zahtjevu 1 do 5, gdje je navedeni IL-8 inhibitor spoj formule (I), gdje je R1 vodik, kiralni atom ugljika fenilpropionske grupe je u S konfiguraciji.
8. IL-8 inhibitor za primjenu prema patentnim zahtjevima 1 do 5, gdje je spomenuti spoj izabran od 2-metil-2-(4-{[4-(trifluorometil)-1,3-tiazol-2-il]amino} fenil) propanske kiseline i njegovih farmaceutski prihvatljivih soli, poželjno njegova natrijeva sol.
9. IL-8 inhibitor za primjenu prema patentnom zahtjevu 1 do 5, gdje je spomenuti spoj (2S)-2-(4-{[4-(trifluorometil)-1,3-tiazol-2-il] amino} fenil) propanska kiselina i njegove farmaceutski prihvatljive soli, poželjno njegova natrijeva sol.
10. IL-8 inhibitor za primjenu prema patentnom zahtjevu 1, naznačen time da je u spomenutom spoju formule (II) kiralni atom ugljika fenilpropionske grupe u R konfiguraciji.
11. IL-8 inhibitor za primjenu prema patentnom zahtjevu 1, gdje je spomenuti spoj izabrani od R-(-)-2-(4-izobutilfenil)propionil metansulfonamida i njegovih farmaceutski prihvatljivih soli, poželjno lizinska in situ sol.
12. IL-8 inhibitor za primjenu prema patentnom zahtjevu 1 do 5, gdje je spomenuti spoj R(-)-2-(4-trifluorometansulfoniloksi)fenil]-N-metansulfonil propionamid i njegove farmaceutski prihvatljive soli, poželjno njegova natrijeva sol.
13. IL-8 inhibitor za primjenu prema patentnim zahtjevima 1 do 12,, pri čemu je spomenuta neuropatija izazvana kemoterapijom inducirana kemoterapijskim agensom izabranim od lijekova na bazi platine, taksana, epotilona, biljnih alkaloida, talidomida, lenalidomida i pomalidomida, karfilzomiba, bortezomiba i eribulina, poželjno navedeni kemoterapijski agens se bira između cisplatina, karboplatina, oksaliplatina, paklitaksela, kabazitaksela, docetaksela, iksabepilona, vinblastina, vinkristina, vinorelbina, etopozida, talidomida, lenalidomida, pomalidomida, karfilzomiba, bortezomiba i eribulina.
14. IL-8 inhibitor za primjenu prema patentnom zahtjevu 13, pri čemu je navedeno kemoterapijsko sredstvo izabrano od taksana i lijekova na bazi platine, poželjno taksan je paklitaksel, a lijek na bazi platine je oksaliplatin.
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP16151618.2A EP3192504A1 (en) | 2016-01-15 | 2016-01-15 | Il-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy |
| EP16190871 | 2016-09-27 | ||
| PCT/EP2017/050637 WO2017121838A1 (en) | 2016-01-15 | 2017-01-13 | Il-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy |
| EP17701646.6A EP3402474B1 (en) | 2016-01-15 | 2017-01-13 | Il-8 inhibitors for use in the treatment of chemotherapy-induced peripheral neuropathy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20211527T1 true HRP20211527T1 (hr) | 2021-12-24 |
Family
ID=57906595
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20211527TT HRP20211527T1 (hr) | 2016-01-15 | 2017-01-13 | Il-8 inhibitori za primjenu u liječenju periferne neuropatije izazvane kemoterapijom |
Country Status (22)
| Country | Link |
|---|---|
| US (1) | US20190015391A1 (hr) |
| EP (1) | EP3402474B1 (hr) |
| JP (1) | JP7049254B2 (hr) |
| KR (1) | KR20180101390A (hr) |
| CN (1) | CN108463219B (hr) |
| AU (1) | AU2017207850B2 (hr) |
| CA (1) | CA3009438A1 (hr) |
| CY (1) | CY1125297T1 (hr) |
| DK (1) | DK3402474T3 (hr) |
| ES (1) | ES2893701T3 (hr) |
| HR (1) | HRP20211527T1 (hr) |
| HU (1) | HUE056606T2 (hr) |
| IL (1) | IL260373B (hr) |
| LT (1) | LT3402474T (hr) |
| MA (1) | MA43861A (hr) |
| MX (1) | MX2018008614A (hr) |
| PL (1) | PL3402474T3 (hr) |
| RS (1) | RS62427B1 (hr) |
| SG (1) | SG11201804484YA (hr) |
| SI (1) | SI3402474T1 (hr) |
| WO (1) | WO2017121838A1 (hr) |
| ZA (1) | ZA201803486B (hr) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR101914358B1 (ko) * | 2017-01-18 | 2018-11-02 | 현대로템 주식회사 | 실내등 제어회로 및 이를 포함하는 철도차량 |
| CN111343973A (zh) * | 2017-10-24 | 2020-06-26 | 多姆皮制药公司 | 用于治疗一些肉瘤的il-8抑制剂 |
| EP3476390A1 (en) | 2017-10-24 | 2019-05-01 | Dompé farmaceutici S.p.A. | Il-8 inhibitors for use in the treatment of sarcomas |
| EP3498269A1 (en) * | 2017-12-12 | 2019-06-19 | Dompé farmaceutici S.p.A. | C5ar inhibitors for use in the treatment of chemotherapy-induced iatrogenic pain |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IT1303249B1 (it) * | 1998-10-23 | 2000-11-06 | Dompe Spa | Alcune n-(2-aril-propionil)-solfonammidi e preparazionifarmaceutiche che le contengono. |
| CN1934077B (zh) * | 2004-03-23 | 2010-09-29 | 冬姆佩制药股份公司 | 2-苯基丙酸衍生物及含有它们的药物组合物 |
| US20090041753A1 (en) * | 2006-09-26 | 2009-02-12 | Miller Robert H | Cytokine signaling |
| EP2166006A1 (en) * | 2008-09-18 | 2010-03-24 | Dompe' S.P.A. | 2-aryl-propionic acids and derivatives and pharmaceutical compositions containing them |
| CR20160557A (es) * | 2014-05-29 | 2017-01-20 | Glaxosmithkline Ip Dev Ltd | Compuestos derivados de 1-(ciclopent-2-en-1-il)-3-(2-hidroxi-3-(arilsulfonil)fenil)urea como inhibidores cxcr2 |
| BR112017002060A2 (pt) * | 2014-07-31 | 2017-12-26 | Glaxosmithkline Ip Dev Ltd | novo uso |
-
2017
- 2017-01-13 MX MX2018008614A patent/MX2018008614A/es unknown
- 2017-01-13 ES ES17701646T patent/ES2893701T3/es active Active
- 2017-01-13 CA CA3009438A patent/CA3009438A1/en active Pending
- 2017-01-13 DK DK17701646.6T patent/DK3402474T3/da active
- 2017-01-13 SI SI201730924T patent/SI3402474T1/sl unknown
- 2017-01-13 LT LTEPPCT/EP2017/050637T patent/LT3402474T/lt unknown
- 2017-01-13 HR HRP20211527TT patent/HRP20211527T1/hr unknown
- 2017-01-13 SG SG11201804484YA patent/SG11201804484YA/en unknown
- 2017-01-13 KR KR1020187019923A patent/KR20180101390A/ko not_active Application Discontinuation
- 2017-01-13 WO PCT/EP2017/050637 patent/WO2017121838A1/en active Application Filing
- 2017-01-13 MA MA043861A patent/MA43861A/fr unknown
- 2017-01-13 JP JP2018537469A patent/JP7049254B2/ja active Active
- 2017-01-13 EP EP17701646.6A patent/EP3402474B1/en active Active
- 2017-01-13 US US16/066,072 patent/US20190015391A1/en active Pending
- 2017-01-13 CN CN201780005946.9A patent/CN108463219B/zh active Active
- 2017-01-13 PL PL17701646T patent/PL3402474T3/pl unknown
- 2017-01-13 AU AU2017207850A patent/AU2017207850B2/en active Active
- 2017-01-13 RS RS20211209A patent/RS62427B1/sr unknown
- 2017-01-13 HU HUE17701646A patent/HUE056606T2/hu unknown
-
2018
- 2018-05-25 ZA ZA2018/03486A patent/ZA201803486B/en unknown
- 2018-07-02 IL IL260373A patent/IL260373B/en active IP Right Grant
-
2021
- 2021-10-14 CY CY20211100886T patent/CY1125297T1/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| JP2019501948A (ja) | 2019-01-24 |
| CN108463219B (zh) | 2021-09-17 |
| RS62427B1 (sr) | 2021-11-30 |
| EP3402474B1 (en) | 2021-07-21 |
| PL3402474T3 (pl) | 2021-12-27 |
| DK3402474T3 (da) | 2021-10-11 |
| BR112018013570A2 (pt) | 2018-12-11 |
| CA3009438A1 (en) | 2017-07-20 |
| SG11201804484YA (en) | 2018-07-30 |
| US20190015391A1 (en) | 2019-01-17 |
| CY1125297T1 (el) | 2023-03-24 |
| CN108463219A (zh) | 2018-08-28 |
| ZA201803486B (en) | 2019-09-25 |
| EP3402474A1 (en) | 2018-11-21 |
| SI3402474T1 (sl) | 2021-12-31 |
| AU2017207850B2 (en) | 2022-06-30 |
| ES2893701T3 (es) | 2022-02-09 |
| MA43861A (fr) | 2021-05-05 |
| HUE056606T2 (hu) | 2022-02-28 |
| AU2017207850A1 (en) | 2018-06-21 |
| WO2017121838A1 (en) | 2017-07-20 |
| JP7049254B2 (ja) | 2022-04-06 |
| MX2018008614A (es) | 2018-11-19 |
| IL260373B (en) | 2021-03-25 |
| LT3402474T (lt) | 2021-11-25 |
| KR20180101390A (ko) | 2018-09-12 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20211527T1 (hr) | Il-8 inhibitori za primjenu u liječenju periferne neuropatije izazvane kemoterapijom | |
| AR108838A1 (es) | Ácidos de carbamoiloximetil triazol ciclohexilo como antagonistas de lpa | |
| PE20230824A1 (es) | Inhibidores alostericos de cromenona del fosfoinositido 3-quinasa (pi3k) para el tratamiento de enfermedades | |
| ES2566482T3 (es) | Derivados de oxazol sustituidos, composición farmacéutica que contiene los derivados, y método para tratar la enfermedad de Parkinson utilizando los mismos | |
| PE20121159A1 (es) | DERIVADOS DE PIRIDINA, PIRAZINA Y QUINOLINA COMO INHIBIDORES DE LA FOSFOINOSITIDA 3 CINASA Y LA mTOR | |
| SI3024819T1 (en) | Glyoxamide-substituted pyrrolamide derivatives and their use as medicines for the treatment of hepatitis B | |
| EA201290260A1 (ru) | Бензимидазол-имидазольные производные | |
| DE15187654T1 (de) | Antivirales Mittel | |
| AR081426A1 (es) | Derivados de pirazol inhibidores del receptor sigma | |
| CO6150158A2 (es) | Piperidinas sustituidas que aumentan la actividad de p53 y su uso | |
| AR113908A1 (es) | Profármacos de catecolamina para uso en el tratamiento de la enfermedad de parkinson | |
| AR056204A1 (es) | Derivados de indano como antagonistas de receptores de mch, metodos para su preparacion, intermediarios de sintesis de los mismos, composiciones farmaceuticas que los comprenden y su uso en la fabricacion de medicamentos para el tratamiento de enfermedades relacionadas | |
| NZ601967A (en) | Pde10 inhibitors and related compositions and methods | |
| AR060401A1 (es) | Derivados de cromen-2-ona | |
| AR049438A1 (es) | Derivados con estructura aroil-o-piperidina, procedimientos para su preparacion, composiciones farmaceuticas que los comprenden y sus aplicaciones terapeuticas | |
| NZ726055A (en) | Quinazolinone derivatives as phosphatidylinositol 3-kinase inhibitors | |
| EA022420B1 (ru) | Гетероциклические ингибиторы глутаминилциклазы (qc, ec 2.3.2.5) | |
| AR072793A1 (es) | Compuestos de aril isoxazol con actividades antitumorales | |
| MA40480B1 (fr) | Procédé de cristallisation de dérivés d'aripiprazole dans des formulations à libération prolongée pour le traitement de la schizophrénie | |
| DOP2012000053A (es) | Derivados de (tio) morfolina como moduladores de s1p | |
| AR074807A1 (es) | Derivados de 1, 3, 4-oxadiazol, composiciones farmaceuticas que los comprenden y su uso en la preparacion de un medicamento para el tratamiento de enfermedades mediadas por la inhibicion de la actividad de la dgat1. | |
| PE20190979A1 (es) | Compuestos de heteroarilcarboxamida como inhibidores de ripk2 | |
| AR082534A1 (es) | Compuestos que interactuan con proteina reguladora de glucocinasa para el tratamiento de diabetes | |
| PE20120732A1 (es) | Agonistas del receptor de esfingosina-1-fosfato | |
| PE20240017A1 (es) | Derivados de 1,2,3,4-tetrahidroquinolina como inhibidores de la activacion de yap/taz-tead para el tratamiento del cancer |